KMT2A and acute myeloid leukemia: Along this line of reasoning, Huang et al. [75] importantly showed in an MLL-AF9-induced AML mouse model that blocking sEV secretion from ECs, but not perivascular cells, megakaryocytes, or spleen stromal cells, markedly delayed leukaemia progression.